Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update

Slide: 23 of 40

Summary of Benefits: Medications

Alendronate, risedronate, zoledronic acid, and denosumab reduce the risk of hip and nonvertebral fractures in postmenopausal women with osteoporosis. The strength of evidence for this conclusion is high.

Bisphosphonates as a class (alendronate, risedronate, zoledronic acid, and ibandronate), as well as denosumab, teriparatide, and raloxifene, reduce the risk of vertebral fractures in postmenopausal women with osteoporosis. The strength of evidence for this conclusion is high.

The combination of alendronate and calcium significantly decreased the risk for any type of clinical fracture when compared with alendronate alone. The strength of evidence for this conclusion is low.

Teriparatide reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis. The strength of evidence for this conclusion is moderate.

Reduced risk of other fracture types and risk reduction in subpopulations is achieved by fewer medications, and the strength of evidence in support of the findings is variable.